fintopic.
Docs Get the API

Lilly acquires Calytrix Bio

7 statements from 7 sources on Nov 16, 2026, 11:45–16:58 UTC
Part of Deals & M&A
News
Updated
Front page

Statements (7)

  1. Bullish

    Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion

    wsj.comHigh importance
  2. Bullish

    Lilly acquired startup Calytrix for $1.5 billion to develop a therapy for rare blood disorders.

    biopharmadive.comHigh importance
  3. Bullish

    Eli Lilly has acquired Calytrix Bio for up to $1.5 billion.

    di.seHigh importance
  4. Bullish

    Calytrix Bio is being acquired by Eli Lilly for up to $1.5 billion in cash

    nasdaq.comHigh importance
  5. Bullish

    Lilly agrees to buy Calytrix Bio for up to $1.5 billion

    bloomberg.comHigh importance
  6. Neutral

    Eli Lilly is acquiring biotech firm Calytrix Bio for a deal that will allow Eli Lilly to expand its biotechnology operations

    breakingthenews.net
  7. Neutral

    Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis.

    prnewswire.comHigh importance